Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (DE:8QQ)
FRANKFURT:8QQ
RESEARCH TOOLSreports
Holding DE:8QQ?
Track your performance easily
8QQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.16 - €5.43
Previous Close€2.85
Volume1.00K
Average Volume (3M)1.39K
Market Cap
€873.74M
Enterprise Value€318.83M
Total Cash (Recent Filing)$670.36M
Total Debt (Recent Filing)$79.46M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Feb 25, 2025EPS Estimate
-€0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding294,665,532
10 Day Avg. Volume650
30 Day Avg. Volume1,386
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.76
Price to Sales (P/S)24.07
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.65
Enterprise Value/Gross Profit8.38
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
€8.76Price Target Upside207.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
AbCellera Biologics News
PremiumCompany Announcements
AbCellera Biologics Reports Q3 2024 Financial Results
PremiumCompany Announcements
AbCellera Biologics Expands Partnership and Advances Pipeline
PremiumCompany Announcements
AbCellera Biologics Earnings Call and Corporate Presentation UpdateBulls Say, Bears Say
Bulls Say
Clinical Development And PipelineManagement confirmed 14 molecules from their pipeline are in the clinic and 95 initiated programs, highlighting active development efforts.
Liquidity And Financial PositionStrong liquidity provides a runway of over three years and a key opportunity to expand the pipeline and partnership portfolio.
Strategic PartnershipsABCL recently expanded its collaboration with large pharma, a positive signal of interest in ABCL's discovery platform.
Bears Say
EarningsAbCellera reported financial results which were below estimates, with a wide EPS miss due to a significant non-cash R&D impairment charge.
Research And DevelopmentResearch fees are likely to decline as the company shifts focus to internal pipeline and co-development programs, potentially impacting short-term revenue growth.
RevenueRevenue of $6.5M fell below expectations, with no milestones achieved during the quarter, highlighting challenges in meeting financial targets.
---
Options Prices
Currently, No data available
---
Ownership Overview
43.49% Insiders
1.57% Mutual Funds
5.46% Other Institutional Investors
48.42% Public Companies and
Individual Investors
8QQ FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was €2.16 and its highest was €5.43 in the past 12 months.
What is AbCellera Biologics’s market cap?
Currently, no data Available
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Feb 25, 2025 which is in 104 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Nov 04, 2024. The company reported -€0.16 earnings per share for the quarter, missing the consensus estimate of -€0.116 by -€0.043.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -€0.12.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 295,366,270 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -€0.16 in its last earnings report, missing expectations of -€0.116. Following the earnings report the stock price went down -8.257%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Among the largest hedge funds holding AbCellera Biologics’s share is Baker Bros Advisors LP. It holds AbCellera Biologics’s shares valued at 81M.
---
AbCellera Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.76 (207.11% Upside)
€8.76 (207.11% Upside)
Blogger Sentiment
Bullish
DE:8QQ Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Bought Shares
Worth $740.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.02%
12-Months-Change
Fundamentals
Return on Equity
-15.55%
Trailing 12-Months
Asset Growth
-7.89%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
---
8QQ Company Deck
---
8QQ Earnings Call
Q3 2024
0:00 / 0:00
---
8QQ Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
8QQ Stock 12 Month Forecast
Average Price Target
€8.76
▲(207.11% Upside)
Technical Analysis
AbCellera Biologics
―
Allogene Therapeutics
―
Immatics
―
Fate Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering 8QQ
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-30.58%
reiterated a buy rating 8 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -30.58% per trade.
---